2025-10-30
MediciNova
Results MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication medicinova.com ↗The research demonstrated that MN-002, the major metabolite of Company’s investigational compound MN-001 (tipelukast), significantly enhanced cholesterol efflux in macrophages by upregulating key transport proteins ABCA1 and ABCG.
2024-05-28
MediciNova
Results MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions medicinova.com ↗MediciNova’s Dr. Huicheng Qi presented “MN-002, THE METABOLITE OF MN-001 (TIPELUKAST) PROMOTES MACROPHAGE CHOLESTEROL EFFLUX (Abstract # 856)”, demonstrating positive data regarding cholesterol efflux capacity by MN-001 (Tipelukast) and MN-002.
2023-08-14
MediciNova
Regulatory MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe medicinova.com ↗
2023-01-10
MediciNova
Regulatory MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada medicinova.com ↗
2023-01-09
MediciNova
Regulatory MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil medicinova.com ↗
2022-12-06
MediciNova
Results MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation medicinova.com ↗today announced that MediciNova’s Chief Medical Officer, Kazuko Matsuda, MD PhD MPH, presented positive results from a subgroup analysis of the completed Phase 2 clinical trial which evaluated MN-001 (tipelukast) for the treatment of hypertriglyceridemia at the International Diabetes Federation (IDF) World Diabetes Congress 2022 held online December 5 - 8, 2022.
2022-08-09
MediciNova
Results MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation medicinova.com ↗We are very pleased to present the additional findings from our completed Phase 2 trial in which MN-001 improved serum lipid profile in the NAFLD participants with Type 2 diabetes more significantly than in the NAFLD participants without Type 2 diabetes.
2022-02-01
MediciNova
Regulatory MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea medicinova.com ↗
2021-11-11
MediciNova
Results MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases medicinova.com ↗As a result, it was found that MN-001 had an inhibitory effect on TG synthesis in HepG2 cells.
2021-10-21
MediciNova
Results MediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021) medicinova.com ↗This study showed that MN-001 (tipelukast) inhibited the uptake of arachidonic acid into hepatocytes and suppressed the synthesis and accumulation of triglycerides (TG) in hepatocytes.
2021-09-01
MediciNova
Results MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases medicinova.com ↗We are very pleased to present new findings from our collaboration with Dr. Ogura which elucidate MN-001’s ability to improve lipid metabolism.
2021-08-12
MediciNova
Results MediciNova Reports Second Quarter 2021 Financial Results and Business Update medicinova.com ↗although our Phase 2 trial in IPF did not demonstrate a clear clinical effect on most of the outcome measures
2020-11-12
MediciNova
Results MediciNova Announces Presentation of Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model at The Liver Meeting Digital Experience™ 2020 medicinova.com ↗MN-001 (D46) significantly attenuated TGFβ1 induced HSC activation
2020-10-13
MediciNova
Results MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020 medicinova.com ↗
2020-01-27
MediciNova
Regulatory MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe medicinova.com ↗today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of idiopathic pulmonary fibrosis (IPF).
2019-10-07
MediciNova
Regulatory MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan medicinova.com ↗
2019-04-22
MediciNova
Regulatory MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in China medicinova.com ↗today announced that it has received a Notice of Allowance from the Chinese Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia.
2018-06-19
MediciNova
Regulatory MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia and Hypercholesterolemia in Japan medicinova.com ↗
2018-04-23
MediciNova
Regulatory MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China medicinova.com ↗
2018-04-23
MediciNova
Regulatory MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia medicinova.com ↗
2018-04-23
MediciNova
Regulatory MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Liver Disorders medicinova.com ↗
2018-04-23
MediciNova
Results MediciNova Announces Positive Results in Study of MN-001 in Mouse Model of Pulmonary Fibrosis medicinova.com ↗
2018-04-23
MediciNova
Results MediciNova Announces Positive Results in NASH Mouse Model With MN-001 and Prepares to Initiate Phase 2 Trial in the U.S. medicinova.com ↗
2018-04-23
MediciNova
Results MediciNova Announces Positive Results of MN-001 in Advanced NASH Mouse Model; MediciNova Requests a Meeting With FDA medicinova.com ↗
2018-04-23
MediciNova
Results MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis medicinova.com ↗MN-001 (tipelukast) significantly reduced mean serum triglycerides, a primary endpoint, from 260.1 mg/dL before treatment to 185.2 mg/dL after eight weeks of treatment (p=0.00006).
2018-04-23
MediciNova
Regulatory MediciNova Announces an Open Investigational New Drug (IND) Application for MN-001 in NASH medicinova.com ↗
2018-04-23
MediciNova
Regulatory MediciNova Announces FDA Granted Orphan Drug Designation to MN-001 (tipelukast) for Idiopathic Pulmonary Fibrosis (IPF) medicinova.com ↗
2018-04-23
MediciNova
Regulatory MediciNova Announces FDA Approval of the Second Phase 2 Protocol for MN-001 in NASH Which Targets NASH Patients With Hypertriglyceridemia medicinova.com ↗
2018-04-23
MediciNova
Regulatory MediciNova Announces FDA Approval of Protocol for Phase 2 Trial of MN-001 in IPF medicinova.com ↗
2018-04-23
MediciNova
Regulatory FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis medicinova.com ↗today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for MN-001 (tipelukast) for the treatment of patients with nonalcoholic steatohepatitis (NASH) with fibrosis.
2018-04-23
MediciNova
Regulatory FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis medicinova.com ↗
2018-04-13
MediciNova
Results MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, France medicinova.com ↗After 8 weeks of treatment with MN-001, the serum triglyceride level was reduced in 14 out of 15 subjects.
Show 20 more releases